

Journal of Visualized Experiments

Three-Dimensional Imaging of the Vertebral Lymphatic Vasculature and Drainage Using iDISCO+ and Light Sheet Fluorescence Microscopy --Manuscript Draft--

Article Type:	Invited Methods Article - JoVE Produced Video
Manuscript Number:	JoVE61099R2
Full Title:	Three-Dimensional Imaging of the Vertebral Lymphatic Vasculature and Drainage Using iDISCO+ and Light Sheet Fluorescence Microscopy
Section/Category:	JoVE Immunology and Infection
Keywords:	meningeal and vertebral lymphatic vasculature, lymph nodes, drainage, iDISCO+, Light Sheet Fluorescence Microscope
Corresponding Author:	Jean-Leon Thomas Yale University School of Medicine Paris, Connecticut FRANCE
Corresponding Author's Institution:	Yale University School of Medicine
Corresponding Author E-Mail:	jean-leon.thomas@yale.edu
Order of Authors:	Jean-Leon Thomas Laurent Jacob Jose Brito Nicolas Renier
Additional Information:	
Question	Response
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the city, state/province, and country where this article will be filmed . Please do not use abbreviations.	Paris, France

Yale University



SCHOOL OF MEDICINE
333 CEDAR STREET, 3 FMP
P.O. BOX 208017
NEW HAVEN, CONNECTICUT 06520-8017

Jean-Leon Thomas, Ph.D.
Associate Professor
Department of Neurology
Yale University School of Medicine

Telephone: 203.737 5044
Fax: 203.785.7144
Email: jean-leon.thomas@yale.edu

February 3, 2020

To Dr. Xiaoyan Cao, Ph.D.
Review Editor
JoVE
617.674.1888
xiaoyan.cao@jove.com

Dear Dr. Cao,

Please find enclosed our manuscript, JoVE61099 "Three-dimensional imaging of the vertebral lymphatic vasculature and drainage using the iDISCO+ protocol and light sheet fluorescence microscopy" which has been revised according to the reviewers' comments. The letter of response to the reviewers is associated with the manuscript.

The removal of Nicolas Renier as a co-author has been made in agreement with him, based on the fact that Nicolas has not contributed substantially to the work shown in the Figures. Nicolas' team also use slightly different image capture and computational procedures than the ones used in the present report.

We hope that you will appreciate this revised version of our manuscript which has a new title and now includes three Tables.

Sincerely,

J-L Thomas, Ph.D.

TITLE:

Three-Dimensional Imaging of the Vertebral Lymphatic Vasculature and Drainage Using iDISCO⁺ and Light Sheet Fluorescence Microscopy

AUTHORS AND AFFILIATIONS:

Laurent Jacob^{1,*}, Jose Brito^{1,2,*}, Jean-Leon Thomas^{1,3}

¹Université Pierre et Marie Curie Paris, Sorbonne Université, Institut du Cerveau et de la Moelle Epinière, Paris, France

²Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

³Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

*These authors contributed equally.

Corresponding Author:

Jean-Leon Thomas (jean-leon.thomas@yale.edu)

Email Addresses of Co-Authors:

Laurent Jacob (laurent.jacob@icm-institute.org)

Jose Brito (jose.debrito@icm-institute.org)

KEYWORDS:

meningeal and vertebral lymphatic vasculature, lymph nodes, drainage, iDISCO⁺, light sheet fluorescence microscope, central nervous system

SUMMARY:

A protocol is presented combining tissue clearing with light sheet fluorescence microscopy (LSFM) to obtain three-dimensional and cellular resolution images of the lymphatic vessels and lymph nodes (LNs) collecting the cerebrospinal fluid (CSF) and spinal epidural fluid.

ABSTRACT:

The lymphatic system associated with the central nervous system (CNS) includes the lymphatic vasculature that spins around the brain, the spinal cord, and its associated LNs. The CNS-associated lymphatic system is involved in the drainage of CSF macromolecules and meningeal immune cells toward CNS-draining LNs, thereby regulating waste clearance and immune surveillance within CNS tissues. Presented is a novel approach to obtain three-dimensional (3D) and cellular resolution images of CNS-associated lymphatics while preserving the integrity of their circuits within surrounding tissues. The iDISCO⁺ protocol is used to immunolabel lymphatic vessels in decalcified and cleared whole mount preparations of the vertebral column that are subsequently imaged with light sheet fluorescence microscopy (LSFM). The technique reveals the 3D structure of the lymphatic network connecting the meningeal and epidural spaces around the spinal cord to extravertebral lymphatic vessels. Provided are 3D images of the drainage circuits of molecular tracers previously injected into either the CSF via the cisterna magna or the thoracolumbar spinal parenchyma. The iDISCO⁺/LSFM approach brings unprecedented

opportunities to explore the structure and function of the CNS-associated lymphatic system in neurovascular biology, neuroimmunology, brain and vertebral cancer, or vertebral bone and joint biology.

INTRODUCTION:

The CNS is surrounded by the CSF and overlaying layers of meninges, epidural tissue, and bones. Altogether, the CSF provides physical protection to the soft brain and spinal cord. It is mainly secreted by the choroid plexus and the meningeal membranes (i.e., the pia mater, the arachnoid, and the dura mater). The CSF-meningeal complex also establishes a functional interface between the CNS tissues and the rest of the body, thereby contributing to CNS homeostasis. First, the CSF penetrates the CNS parenchyma through the CNS para-arterial spaces and interacts dynamically with the interstitial fluid (ISF)¹ via the glymphatic (glia-lymphatic) system, which consists of the paravascular spaces and the astrocyte end-feet membranes around the CNS vessels²⁻⁴. Metabolic waste and excess fluid are then ultimately cleared by intramural perivascular drainage directly from the brain parenchyma toward the systemic circulation³, as well as the paravenous spaces toward the CSF and via brain-draining lymphatic vessels, according to the glymphatic model^{2,4}. CSF outflow is mainly via the lymphatic system, through the cribriform plate and associated extracranial lymphatic vessels⁵⁻⁷, as well as by the meningeal lymphatic vessels, which converge at the brain-draining LNs⁸⁻¹² (**Figure 1**). An important, although secondary, role in CSF outflow is taken by the cranial arachnoid villi, which penetrate the lacuna of meningeal venous sinuses¹³.

The CFS drainage circuits have been extensively investigated through experimental approaches based on the injection of colored/fluorescent tracers into the CNS or CSF, followed by the imaging of the tracers' pattern inside the CNS and throughout the body organs and tissues at different timepoints after injection¹³. For a long time, the outflow of CSF was considered to be exclusively and directly taken in charge by the blood circulation, through arachnoid villi projecting into dural venous sinuses¹³. However, the CSF outflow is predominantly performed by the lymphatic vasculature, as recently shown by near-infrared (NIR) dynamic imaging of CSF-injected tracer transport in mice^{9,10}. The CSF-draining lymphatic vessels then return lymph to the bloodstream via the right subclavian vein. Complementary approaches have detected both extracranial^{6,7,13} and intracranial⁹⁻¹² lymphatic exits of CSF-injected tracers and suggest that the CSF is absorbed by two lymphatic pathways, one external and the other one internal to the skull and vertebral column. The main part of CSF drainage rapidly occurs through lymphatic vessels located rostrally, outside of the skull in the nasal mucosa, through channels of the cribriform plate of the ethmoid bone^{3,6,13} and, caudally, outside of lumbosacral vertebral bones through dorsolateral routes that are not yet fully characterized^{7,14}. In addition, in the meninges of the skull, lymphatic capillaries of the dura mater directly absorb CSF and meningeal immune cells toward dural lymphatic collectors that cross the skull bones and connect to CNS-draining LNs^{12,14}. These meningeal lymphatic vessels play important roles in CNS pathophysiology, because brain meningeal lymphatics are altered upon aging and also impact the outcome of neurological brain diseases, including neurodegeneration, neuroinflammation, and brain cancer¹⁵⁻¹⁷. Therefore, the CNS-associated lymphatic vasculature (i.e., the dural and peripheral lymphatic vessels draining the CSF) may be a promising novel target to combat CNS diseases in humans.

Convergent studies performed with immunohistology and high-resolution magnetic resonance imaging demonstrated that the meningeal lymphatic vasculature also exists in primates, including common marmoset monkeys and humans^{7,11,13}. Moreover, meningeal lymphatic vessels are not restricted to the skull, but extend within the vertebral column to the surface of spinal ganglia and rami^{13,18}. Three-dimensional (3D) imaging of the vertebral column lymphatics preserving the overall anatomy of labeled vertebral and spinal samples, including overlying bones, muscles, ligaments, as well as neighboring visceral tissues, was recently performed¹⁴. The iDISCO⁺ protocol^{19,20} was used to immunolabel decalcified and cleared preparations of the whole vertebral column with lymphatic-specific antibodies against either the membrane receptor LYVE1²¹ or the transcription factor PROX1²². Image acquisition and analysis were then carried out with light sheet fluorescence microscopy (LSFM) and the Imaris software. LSFM allows for rapid and minimally invasive 3D imaging of large specimens by axial confinement of illumination, which results in reduced photobleaching and phototoxicity²³.

The iDISCO⁺/LSFM approach allows characterization of the distinct layers of dural and epidural lymphatic vessels, and the connection of this vasculature to the extravertebral lymphatic circuits and the LNs neighboring the vertebral column. The protocol was applied to tissues previously injected with fluorescent tracers to demonstrate vertebral canal drainage. The present paper provides details on the iDISCO⁺/LSFM methodology to image the vertebral lymphatic vasculature and illustrates its relevance to CSF and epidural fluid drainage investigation.

PROTOCOL:

All in vivo procedures used in this study complied with all relevant ethical regulations for animal testing and research, in accordance to the European Community for experimental animal use guidelines (L358-86/609EEC). The study received ethical approval by the Ethical Committee of INSERM (n°201611011126651) and the Institutional Animal Care and Use Committee of ICM (Institut du Cerveau et de la Moelle épinière).

1. Preparation

1.1. Prepare the following dissection tools for surgery: scalpel (1), microforceps (2), forceps (1), dissection scissors, and Michel suture clips. Prepare 26 G needles (0.45 mm x 13 mm), 1 mL syringe, and 10 µL microsyringe.

1.2. Pull microcapillaries with a single-step protocol at 67.5 °C with a glass micropipette puller. Prepare two microcapillaries per injection.

1.3. Prepare reagents for imaging lymphatic drainage (**Table 1**): Ovalbumin Alexa Fluor 555 conjugate (OVA-A⁵⁵⁵, 2 mg/mL in 1x phosphate buffered saline [PBS]) and anti-LYVE1 antibody (1 mg/mL in 1x PBS).

1.4. Prepare antibodies (**Table 1**) for iDISCO⁺. For primary antibodies, use anti-LYVE1 rabbit polyclonal antibody (1:1,600) and anti-PROX1 goat polyclonal IgG antibody (1:2,000). For

secondary antibodies, use Alexa Fluor donkey anti-rabbit-568, donkey anti-rabbit-647, and donkey anti-goat-647 (1:2,000).

2. Surgery procedures for intra-cisterna magna (ICM) and thoracolumbar (ThLb) injections

2.1. Preparation of the animal for surgery

2.1.1. Use adult male and female C57BL6/J mice, 8–12-weeks-old.

2.1.2. Inject the mouse intraperitoneally (IP) with 0.015 mg/mL buprenorphine solution diluted in 0.9% sodium chloride at 0.1 mg/kg, 15 min before surgery.

2.1.3. Anesthetize the mouse in an induction box with 2–3% isoflurane gas.

2.2. Preparation of anesthetized animal for tracer injection

2.2.1. Place the anesthetized mouse and its heating pad on the stereotaxic apparatus. Use ear bars to hold the mouse's head, and lay down the body at a ~135° angle to the head. Pinch the tail or the paw with the forcep to check the efficiency of anesthesia.

2.2.2. Inject IP 200 µL of 0.9% sodium chloride for mouse hydration.

2.2.3. Using a scalpel blade, make a skin incision, either in the occipital region toward the cervical region for ICM injection, or at the ThLb vertebral level (Th10-L3) for injection into the ThLb spinal parenchyma.

2.3. Tracer injection

2.3.1. Immobilize the spinal cord at the ThLb vertebral level (Th12-L1) with a spinal adaptor. Discard paracervical and paraspinal muscles covering the neck and the column to visualize the surface of the dura mater, the outermost layer of the meninges.

2.3.2. Carefully punctate the central area of the dura mater and underlying arachnoid with a 26 G needle.

2.3.3. Microcapillary implantation

2.3.3.1. Cut 2 mm of the glass capillary tip (see step 1.2), then use the microcapillary connected to a cannula linked to a 10 µL syringe to aspirate 2–8 µL of the OVA-A⁵⁵⁵ or LYVE1 antibody.

2.3.3.2. Introduce the microcapillary in the medial region of the dura mater at a 30° angle for ICM injections or 10° angle for ThLb spinal injections, and push it in to 1.5 mm below the dura mater.

NOTE: The ligament is punctured, but no laminectomy is performed.

2.3.3.3. Add 10 μ L of surgical glue to close the incision around the glass capillary and wait for it to dry.

2.3.4. Slowly inject the fluorescent tracer at 1 μ L/min. Once the injection volume has been delivered, maintain the capillary in place for 1 min. Retract the microcapillary and add surgical glue to close the injection hole.

2.4. Postinjection, close the skin incisions with suture clips. Remove the mouse from the stereotaxic apparatus and place it in a postsurgery warming chamber at 37 °C until it recovers.

3. Perfusion and tissue dissection

3.1. At either 15 min or 45 min after CSF tracer injection, inject IP a lethal dose (100 μ L) of sodium pentobarbital. Pinch the tail or the paw to verify that there is no reflex.

3.2. With dissection scissors, cut the skin and open the peritoneal layer from the lower abdomen region toward the thoracic cage. Open the thoracic cage with scissors to have access to the heart.

3.3. Insert the 26 G needle in the left ventricle of the heart and start to perfuse with 20 mL of ice-cold 4% paraformaldehyde (PFA) in 1x PBS at 2 mL/min. Use scissors to rapidly cut the right atrium and release the perfusion fluid stream.

3.4. Completely remove the skin with forceps and cut the four legs with scissors. Remove all the internal organs but be careful to preserve the LNs intact.

NOTE: Mandibular LNs are superficial, so take care to not remove them when cutting off the skin. Deep-cervical LNs (dcLNs) are located on each side of the trachea, in contact with the lateral surface of the internal jugular veins and close to the stereomastoid muscles.

3.5. Cut the ribs to remove the vertebral column with the spinal cord inside from the cervical to the lumbar segments.

3.6. Immerse the dissected tissues in ice-cold 4% PFA in 1x PBS in a 50 mL tube overnight (~18 h) at 4 °C. Wash the fixed tissues 3x in 50 mL of 1x PBS for 5 min.

4. Fluorescence macroscopy of a vertebral segment

4.1. Position the sample under the fluorescence stereozoom microscope with a camera (**Table of Materials**). Take an overview of the sample or zoom on a specific region.

5. Sample preparation for whole mount immunostaining

5.1. Using a microtome blade, transversally cut the head-and-vertebral column at the occipital and cervical levels.

NOTE: This dissection allows isolation of the head and the cervical vertebral region from the rest of the vertebral column.

5.2. With a microtome blade, cut the cervical, thoracolumbar, and sacral regions of the vertebral column transversally into segments of 2–4 vertebrae, about 0.5 cm size each.

5.3. Isolate each segment in the order it was separated from the vertebral axis, along the entire length of the cervical and thoracic regions of the vertebral column. Preserve each sample in a tube of 2 mL 1x PBS.

6. iDISCO⁺ whole mount immunostaining of a vertebral segment

NOTE: The detailed description of the iDISCO⁺ protocol is accessible at <http://www.idisco.info>.

6.1. Day 1: Tissue dehydration

6.1.1. Dehydrate vertebral tissue samples (i.e., a vertebral segment) by successive immersion in 20%, 40%, 60%, 80%, and 100% methanol in 1x PBS for 1 h with agitation.

6.1.2. Incubate the samples overnight in a solution of 33% methanol/66% dichloromethane (DCM) at room temperature (RT) with agitation.

6.2. Day 2: Tissue bleaching

6.2.1. Wash samples 2x with 100% methanol for 1 h at RT. Incubate the samples in 5% H₂O₂ in methanol (30% H₂O₂ and methanol 1:5 v/v) at 4 °C overnight.

6.3. Day 3: Decalcification and permeabilization step

6.3.1. Rehydrate the samples gradually in 80%, 60%, 40%, 20% methanol, then in 1x PBS (1 h in each solution) at RT with agitation.

6.3.2. Decalcify the vertebrae by incubating samples in Morse's solution (10% trisodium citrate and 45% formic acid 1:1 v/v) for 30 min at RT to preserve the bone structure.

6.3.3. Rinse the samples 2x with 1x PBS and incubate 2x for 1 h in PTx2 solution (0.2% Triton X-100 in 1x PBS, renew for the second incubation) at RT with agitation. Then incubate the pretreated samples in permeabilization solution (PTx2 with 20% dimethyl sulfoxide [DMSO] and 2.3% w/v glycine) at 37 °C for 24 h.

6.4. Day 4: Blocking step

264
265 6.4.1. Incubate samples in blocking solution (PTx2 with 6% donkey serum and 10% DMSO) at
266 37 °C for 24 h.

267 268 6.5. Days 5–16: Whole mount immunolabeling

269
270 6.5.1. Incubate samples in primary antibody diluted in PTwH (1x PBS containing 0.2% Tween-20
271 and 0.1% heparin at 10 mg/mL in 1x PBS) with 5% DMSO/3% donkey serum at 37 °C for 6 days.
272 Wash samples 4–5x in PTwH at RT with agitation overnight.

273
274 6.5.2. Incubate samples in secondary antibody dilutions in PTwH with 3% donkey serum at 37 °C
275 for 4 days. Wash samples in PTwH 4–5x at RT under agitation overnight before clearing.

276 277 6.6. Days 17 and 18: iDISCO⁺ tissue clearing

278
279 6.6.1. Dehydrate samples gradually by successive immersion in 1x PBS, then 20%, 40%, 60%, 80%,
280 and 2x in 100% methanol (1 h in each solution). Incubate each sample overnight in a solution of
281 33% methanol/66% DCM.

282
283 6.6.2. Wash 2x in 100% DCM for 15 min to remove the methanol. Incubate in dibenzyl ether (DBE)
284 without shaking until cleared (4 h) and then store in DBE at RT before imaging.

285 286 7. LSFM imaging

287
288 7.1. Image cleared samples in a transversal plane with the LSFM equipped with a 4x/0.3 objective.

289
290 7.1.1. Use a single sided three sheet illumination configuration, fixed x position (no dynamic
291 focusing). Use LED lasers tuned to 561 nm, 100 mW; and 639 nm, 70 mW. Set the light sheet
292 numerical aperture to 0.03.

293
294 7.1.2. Use different emission filters: 595/40 for Alexa Fluor-568 or -555, and -680/30 for Alexa
295 Fluor-647.

296
297 7.2. Fill the microscope chamber with DBE.

298
299 7.3. Acquire stacks with 2.5 μm z steps and a 30 ms exposure time per step with the camera (**Table**
300 **of Materials**). Use the x2 optical zoom for an effective magnification of (x8), 0.8 μm /pixel, and
301 perform the mosaic acquisitions with a 10% overlap on the full frame.

302
303 7.4. Acquire images in .tif format with acquisition software and convert them into 3D format with
304 a file conversion software.

305

7.5. Reconstruct mosaics acquisition with stitcher software (Table of Materials). Open the images and move manually to reconstitute the whole mosaic picture, using the 10% overlap between images as a guideline.

7.6. Use the 3D software (Table of Materials) to generate orthogonal projections of data, as shown in Figure 1, Figure 2, Figure 3, and Figure 4, and add a color code attribute to the lymphatic vessels and the other anatomical structures on display. Set a gamma correction of 1.47 to the raw data obtained from the LSFM according to the manufacturer's instructions.

REPRESENTATIVE RESULTS:

3D imaging of the vertebral lymphatic vasculature

Figure 1 presents the steps of the iDISCO⁺/LSFM procedure and a LSFM image of lymphatic circuits inside the vertebral canal of iDISCO⁺-treated ThLb vertebrae. The combination of iDISCO⁺ with LSFM preserved the vertebral anatomy and captured a view of the lymphatic vascular network (i.e., the intravertebral vessels connected with the extravertebral vessels exiting dorsally and laterally from the vertebral body) within the surrounding bones, ligaments, muscles, and nerve ganglia.

Fluorescence macroscopy imaging of dcLN drainage

In order to image macromolecule drainage in the CNS-associated lymphatic system, macromolecular tracers were administrated in vivo by injection into either the CSF or the spinal parenchyma. A macromolecular tracer can be easily delivered into the CSF at the cisterna magna. The cisterna magna is located between the cerebellum and the dorsal surface of the medulla oblongata, above the foramen magnum. Macromolecular tracer can also be injected into the spinal parenchyma by stereotactic surgery at different levels along the vertebral column.

The macromolecular tracers used were either directly labeled with a fluorophore or detected postmortem by immunohistochemistry with specific antibodies. Figure 2A illustrates the experimental plan for tracking OVA-A⁵⁵⁵, a red fluorescent and small molecular weight tracer (around 45 kDa), that was injected into either the CSF (Figure 2B) or the ThLb region of the spinal cord (Figure 2C).

At 45 min after the macromolecular tracer injection, the mice were sacrificed, perfused with 4% PFA, and processed to isolate dissected segments of the brain stem region of the head and the vertebral column that were decalcified and clarified. Macromolecule drainage was then readily assessed by fluorescence macroscopy imaging of the LNs that collect the CSF and epidural fluids. As shown in Figure 2, OVA-A⁵⁵⁵ injection into either the CSF (Figure 2B) or the ThLb (Figure 2C) region of the spinal cord resulted in OVA-A⁵⁵⁵ accumulation into the dcLNs at 45 min after injection. This observation indicates the uptake and drainage of fluorescent tracer by the lymphatic system; it is a prerequisite before pursuing the iDISCO⁺/LSFM procedure to image the vertebral lymphatic drainage.

3D imaging of macromolecule drainage in the vertebral lymphatic system

Based on the detection of OVA-A⁵⁵⁵ labeling in dcLNs, the iDISCO⁺/LSFM procedure could be applied to decalcified and precleared vertebral samples isolated from OVA-A⁵⁵⁵-injected mice. This approach allowed the creation of a 3D map of the lymphatic drainage of CSF and spinal epidural fluid at a specific time point after tracer injection. This 3D mapping could be performed by imaging successive CNS segments, at each level of vertebral column, from the injection point.

Figure 3A shows the experimental design for OVA-A⁵⁵⁵ injection into the ThLb spinal parenchyma and the resulting 3D pattern of OVA-A⁵⁵⁵ distribution in a cervical and a thoracic vertebral segment, in conjunction with the lymphatic vasculature. At 45 min after OVA-A⁵⁵⁵ injection, OVA-A⁵⁵⁵ accumulation was detected in spinal cord tissues and dcLNs (white arrows in **Figure 3B**), in agreement with microscope observations illustrated in **Figure 2**. It was not detected, however, in the cervical and thoracic lymphatic vasculature labeled with anti-LYVE1 antibodies. The absence of CSF-injected tracer in the vertebral lymphatic vessels may be due to either a short persistence time of tracer inside lymphatic vessels or a lack of uptake of the tracer by the lymphatic vessels (**Figure 3C**).

To test the first hypothesis, the rabbit anti-LYVE1 antibody was used as a lymphatic endothelial cell tag to bind CNS-associated lymphatic vessels. The injected rabbit anti-LYVE1 antibody was thereafter detected by immunohistochemistry with an anti-rabbit secondary antibody, while lymphatic endothelial cells were immunolabeled with anti-PROX1 antibodies. **Figure 4** represents the experimental design of anti-LYVE1 injection into the ThLb spinal parenchyma (**Figure 4A**), and the resulting 3D distribution pattern of LYVE1 antibodies in a ThLb segment close to the injection site, with respect to PROX1⁺ lymphatics (**Figure 4B**). Both vertebral lymphatics and their extravertebral lymphatic connections were labeled by injected anti-LYVE1 antibodies, which substantiated the tracer uptake by vertebral lymphatic vessels and the lymphatic drainage toward the extravertebral lymphatic system. LNs were lacking in the ThLb region and, thus, could not be visualized in the imaged segment. Furthermore, the discontinuous pattern of LYVE1 marker observed along lymphatic vessels likely reflected the discontinuous expression of LYVE1 in the lymphatic vasculature, as reported in previous studies^{14,21}. Altogether, the results of the present study demonstrated that, at 45 min after tracer injection, LYVE1 antibody, but not OVA-A⁵⁵⁵, allowed detection of local vertebral lymphatic uptake and was preferable to OVA-A⁵⁵⁵ as a persistent marker of local vertebral lymphatic drainage.

FIGURE AND TABLE LEGENDS:

Figure 1: Three-dimensional view of the vertebral lymphatic vasculature. (A) Schematic representation of the protocol. (B) Planar projection of a 3D view of the ThLb vertebral lymphatic vasculature from a dorsofrontal perspective. Lymphatic vessels were immunolabeled with the anti-PROX1 antibody (green) using the iDISCO⁺ protocol and then imaged by LSFM. Note the metameric-like pattern of the vasculature within the vertebral canal of three successive vertebrae (white arrowheads). In addition to semicircular dorsal vessels (white arrowheads), each vertebral network included ventral branches (yellow arrows), bilateral lateral exit pathways along the spinal rami and ganglia (white arrows), as well as a dorsal exit route at the midline (white double arrow). Vertebral networks were interconnected with a longitudinal vessel (purple arrows). For a

complete description, see Jacob L. et al.¹⁸ SC = spinal cord; Asterisk = ventral vertebral body; D = dorsal; L = lateral; V = ventral; Scale bars = 300 μ m.

Figure 2: dcLNs collected OVA-A⁵⁵⁵-labeled CSF Fluids. (A) Scheme of the experimental design. OVA-A⁵⁵⁵ was injected into either the ICM or the ThLb spinal parenchyma, then mice were sacrificed 45 min after injection. The samples were cleared and observed by fluorescence macroscope imaging (B,C). Fluorescence macroscope images of cervical vertebrae from ICM- (B) and ThLb- (C) injected mice. Note that OVA-A⁵⁵⁵ accumulated in the dcLNs (B,C, white arrowheads), the pial and paravascular spaces of the cervical spinal cord (B,C) and after ICM injection, in ventrolateral exit routes, likely along cervical nerves (B, white arrows). SC = spinal cord. Asterisk = ventral vertebral body; D = dorsal; L = lateral; V = ventral; Scale bars in B and C = 2 mm.

Figure 3: Detection of OVA-A⁵⁵⁵-labeled CSF fluids in the vertebral lymphatic system. (A) Scheme of the experimental design. OVA-A⁵⁵⁵ was injected into the ThLb spinal parenchyma, then mice were sacrificed at 45 min after injection. The samples were treated with the iDISCO⁺ protocol and imaged with a LSFM. (B,C) Planar projections of LSFM-captured frontal 3D views of cervical (B) and thoracic (C) spine segments. OVA-A⁵⁵⁵ accumulation (red) was detected in spinal cord tissues and dcLNs (B, white arrow), as illustrated in Figure 2, but not in the cervical and thoracic lymphatic vasculature immunolabeled here with anti-LYVE1 antibodies (green). SC = spinal cord; Asterisk = ventral vertebral body; D = dorsal; L = lateral; V = ventral; Scale bars = 1 mm (B), 300 μ m (C).

Figure 4: Detection of vertebral lymphatic drainage after intraspinal injection of anti-LYVE1 antibodies. (A) Scheme of the experimental design. Anti-LYVE1 antibodies were injected into the ThLb spinal parenchyma, then mice were sacrificed 45 min after injection. The samples were treated with the iDISCO⁺ protocol and imaged with a LSFM. (B). Planar projections of frontal 3D views of a ThLb (B) spine segment, captured with a LSFM. Anti-LYVE1 antibodies were detected with anti-rabbit antibodies (purple) and the lymphatic vasculature with anti-PROX1 antibodies (green). White vessels are PROX1⁺ lymphatics colabeled with anti-LYVE1 antibodies (B); these include vertebral (yellow arrows) and extravertebral (double yellow arrows) lymphatics. SC = spinal cord; Asterisk = ventral vertebral body; D = dorsal; L = lateral; V = ventral; Scale bars = 300 μ m (B).

Table 1: Antibodies and tracers used in the study.

Table 2: Troubleshooting advice for each step of the protocol, including possible issues and solutions.

DISCUSSION:

The iDISCO⁺/LSFM protocol provides unprecedented 3D views of the CNS-associated lymphatic network within its surrounding tissues at a cellular resolution level. This protocol is well adapted to medium size samples, not exceeding 1.5 cm³, due to the limitations of the LSFM optical system, the reduced working distance, and the large size of commercial objective lenses for high-

resolution microscopy²³. This limitation prevents capturing the whole brain-associated lymphatic system. It is important to note that the area of investigation has to be cautiously delimited and the tissues surrounding the CNS have to be carefully dissected in order to include the extracranial lymphatic vessels and LNs that contribute to the whole lymphatic circuitry (**Table 2**).

In addition to size and anatomical considerations, the complexity of surrounding mesenchymal tissues varies along the skull and vertebral column, which requires adaptation of the decalcification and preclearing treatment in order to obtain a homogeneous sample clarification and allow light beam propagation within a soft isotropic biological tissue. In the absence of bones, LFSM imaging of the brain or spinal cord tissues does not necessitate the decalcification step, and the final resolution of the captured images is optimal¹⁹. The above described protocol, which includes a mild decalcification step with Morse's solution, is well adapted for LFSM imaging of the vertebral column as illustrated in **Figure 1** and **Figure 4**. In contrast, the neck region displays a particularly complex bone anatomy in addition to multiple layers of muscles, fat, and glandular tissues, which reduce the quality of captured LFSM images, as reflected in **Figure 3B**. LFSM imaging of the neck and cervical area may thus be improved by a more stringent treatment of tissues; for example, with EDTA, as previously reported²⁴. The decalcification step is therefore critical and decalcification conditions have to be previously tested for each antibody used before starting the full iDISCO⁺ protocol (**Table 2**).

While the iDISCO⁺/LFSM protocol allows generation of a 3D view of connecting circuits between the meningeal and epidural spaces and associated LNs, the direct quantitative analysis of lymphatic vasculature from LFSM-captured images is not feasible for the following reasons: 1) delineation of lymphatic vessel circuits is unreliable due to the discontinuous pattern of lymphatic marker expression, because membranar LYVE1 is heterogenously distributed²¹ and PROX1 has a nuclear expression pattern²²; 2) the heterogenous penetration of antibodies, as well as the anisotropy that may persist in the biological tissue due to incomplete and heterogenous decalcification and preclearing. LFSM imaging thus needs to be extended by virtual reality tools that enable interactive visualization and thus facilitate quantification of the lymphatic vasculature (www.syglass.io). It is also noteworthy that the precise description of the CNS-associated circuitry requires backing up LFSM information with high-resolution confocal data obtained by conventional immunolabeling on thin (5–10 μ m) cryostat or paraffin-embedded tissue sections, especially to precisely localize the position of lymphatic vessels with regards to the dura mater and the CSF, as reported previously^{11,14,18}.

The iDISCO⁺/LFSM protocol allows three-dimensional visualization of the macromolecular drainage in the CNS-associated lymphatic system, as illustrated in **Figure 3** and **Figure 4**. However, the functional assessment of lymphatic drainage requires, in addition to the recommendations on the iDISCO⁺/LFSM protocol detailed above, following a rigorous procedure, as the final outcome depends on the quality of the injection surgery, the choice of the delivery site, the type and injected volume of macromolecule marker used, and the time of sacrifice after tracer administration (**Table 2**). Due to variations of the tracer pattern between injected animals, the characterization of lymphatic drainage circuits requires large experimental groups (>10 by injection condition). In the protocol presented, 1) the dura mater must be punctured before

injection to prevent unwanted lesions and penetration into the CNS tissues; 2) the injected volume has to be less than 2 μ L to limit unwanted diffusion through the injection hole, along the injection capillary, into the epidural space or extravertebral tissues; 3) the deepness of injection capillary insertion has to be limited to 2 mm below the dura mater to avoid CNS injury or mistargeting in ICM and intraspinal injections, respectively. Note also that a complementary high-resolution confocal analysis of neighboring vertebral segments needs to be performed, as indicated above, to assess the presence of injected tracer inside of the lymphatic vessels. This analysis requires establishing the intensity profile plots for the tracer and the lymphatic marker on cross sections of marker-labeled lymphatic vessels. This approach has been previously used to demonstrate OVA⁵⁵⁵ uptake by ThLb lymphatics at 15 min after injection (Supplementary Figure 5F in Jacob et al.¹⁴). However, it has not been illustrated for the anti-LYVE1 tracer in the present study (**Figure 4**).

Among possible CSF tracers, OVA-A⁵⁵⁵ is an excellent option as it is resistant to the iDISCO⁺ protocol treatments and maintains high fluorescence for LSFM imaging. However, note that the type of tracer must be chosen in accordance with the analysis time point (**Table 1** and **Table 2**). As reported above, OVA-A⁵⁵⁵ labeling of local vertebral lymphatic vessels is observed at 15 min after injection¹⁴. However, OVA-A⁵⁵⁵ is no longer detected in these local lymphatic circuits at 45 min after injection (**Figure 3**) in contrast to the anti-LYVE1 antibody (**Figure 4**).

To conclude, the iDISCO⁺/LSFM protocol is well adapted for investigating the 3D structure and drainage of the CNS-associated lymphatic system in physiological and pathological conditions such as CNS and vertebral column cancers, or vertebral bone and joint diseases. Although the full procedure is long and requires methodological rigor, it provides valuable, unique information when used with complementary analysis using virtual reality tools and high-resolution confocal imaging.

ACKNOWLEDGMENTS:

This work was supported by Institut National de la Sante et de la Recherche Medicale, Agence Nationale Recherche (ANR-17-CE14-0005-03), Federation pour la Recherche sur le Cerveau (FRC 2017), Carnot Maturation (to L.J.), Universidade Federal de Rio de Janeiro (UFRJ for J.B.), NIH (R01EB016629-01) and the Yale School of Medicine. We acknowledge the ICM platforms: ICM-QUANT for cellular imaging and ICM-histomics for immunohistochemistry. All animal work was conducted at the PHENO-ICMice facility. The Core is supported by 2 “Investissements d’avenir” (ANR-10-IAIHU-06 and ANR-11-INBS-0011-NeurATRIS) and the “Fondation pour la Recherche Médicale”. We acknowledge Nicolas Renier for methodological advice and manuscript reading.

DISCLOSURES:


The authors have nothing to disclose.


REFERENCES:



1. Plog, B. A., Nedergaard, M. The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future. *Annual Review of Pathology*. **13**, 379–394 (2018).


2. Iliff, J. J., Goldman, S. A., Nedergaard, M. Implications of the discovery of brain lymphatic pathways. *The Lancet Neurology*. **14** (10), 977–9795 (2015).
3. Engelhardt, B. et al. Vascular, glial, and lymphatic immune gateways of the central nervous system. *Acta Neuropathologica*. **132**, 317–338 (2016).
4. Benveniste, H. et al. The Glymphatic System and Waste Clearance with Brain Aging: A Review. *Gerontology*. 1–14 (2018).
5. Louveau, A., Da Mesquita, S., Kipnis, J. Lymphatics in Neurological Disorders: A Neuro-Lympho-Vascular Component of Multiple Sclerosis and Alzheimer's Disease? *Neuron*. **91** (5), 957–973 (2016).
6. Ma, Q., Ineichen, B. V., Detmar, M., Proulx, S. T. Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice. *Nature Communications*. **8** (1), 1434 (2017).
7. Ma, Q., Decker, Y., Müller, A., Ineichen, B. V., Proulx, S. T. Clearance of cerebrospinal fluid from the sacral spine through lymphatic vessels. *The Journal of Experimental Medicine*. **216** (11), 2492–2502 (2019).
8. Louveau, A. et al. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. *The Journal of Clinical Investigation*. **127** (9), 3210–3219 (2017).
9. Louveau, A. et al. Structural and functional features of central nervous system lymphatic vessels. *Nature*. **523** (7560), 337–341 (2015).
10. Aspelund, A. et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *The Journal of Experimental Medicine*. **212** (7), 991–999 (2015).
11. Antila, S. et al. Development and plasticity of meningeal lymphatic vessels. *The Journal of Experimental Medicine*. **214** (12), 3645–3667 (2017).
12. Ahn, J. H. et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. *Nature*. **572** (7767), 62–66 (2019).
13. Pollay, M. The function and structure of the cerebrospinal fluid outflow system. *Cerebrospinal Fluid Research*. **7**, 9 (2010).
14. Jacob, L. et al. Anatomy and function of the vertebral column lymphatic network in mice. *Nature Communications*. **10** (1), 1–16 (2019).
15. Louveau, A. et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. *Nature Neuroscience*. **21** (10), 1380–1391 (2018).
16. Da Mesquita, S. et al. Functional aspects of meningeal lymphatics in ageing and Alzheimer's disease. *Nature*. **560** (7717), 185–191 (2018).
17. Song, E. et al. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours. *Nature*. **577** (7792), 689–694 (2020).
18. Absinta, M. et al. Human and nonhuman primate meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. *eLife*. **6**, e29738 (2017).
19. Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging. *Cell*. **159** (4), 896–910 (2014).
20. Renier, N. et al. Mapping of Brain Activity by Automated Volume Analysis of Immediate Early Genes. *Cell*. **165** (7), 1789–1802 (2016).
21. Jackson, D. G., Prevo, R., Clasper, S., Banerji, S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. *Trends in Immunology*. **22** (6), 317–321 (2001).

- 566 22. Wigle, J. T., Oliver, G. Prox1 function is required for the development of the murine lymphatic
567 system. *Cell*. **98** (6), 769–778 (1999).
- 568 23. Olarte, O. E., Andilla, J., Gualda, E. J., Loza-Alvarez, P. Light-sheet microscopy: a tutorial.
569 *Advances in Optics and Photonics*. **10** (1), 111–179 (2018).
- 570 24. Jing, D. et al. Tissue clearing of both hard and soft tissue organs with the PEGASOS method.
571 *Cell Research*. **28** (8), 803–818 (2018).









Reagents	Target	Figure	Protocol step
OVA-A ⁵⁵⁵	CSF tracer	Figure 2 and Figure 3	2. ICM or ThLb injection 7. LSFM imaging.
Anti-Lyve1 antibody	Membrane marker of LVs cells	Figure 3	6. iDISCO ⁺ whole mount immunostaining. 7. LSFM imaging.
	Tracer drainage of the dural and epidural LVs	Figure 4	2. ICM or ThLb injection 6. iDISCO+ whole mount immunostaining 7. LSFM imaging
Anti-Prox1 antibody	Nuclear marker of LVs cells	Figure 1 and Figure 4	6. iDISCO ⁺ whole mount immunostaining 7. LSFM imaging

Comment
Water soluble, easy to inject and high intense fluorescence
Efficient antibody to whole mount immunostaining
Efficient antibody to whole mount immunostaining

	Problem	Possible reason
Surgery for tracer injection	Unwanted CNS tissue lesion	1. Lack of control of glass capillary insertion 2. Incorrect depth of glass capillary insertion
	Unwanted defilement of injected tracer into the epidural or extra-vertebral spaces	Incorrect injection of tracer
		Excessive volume of injected tracer
iDISCO ⁺ immunostaining	Absence, heterogeneity or excessive background of labeling in the tissue	1. Issues with the concentration of the primary antibody 2. Insufficient permeabilization 3. Insufficient washing 4. Insufficient clearing
		Insufficient decalcification
iDISCO ⁺ clearing	Samples are opaque or brown-colored	Insufficient bleaching
		Presence of oxidation
		Insufficient clearing
Tracer detection	Undetectable tracer	Incorrect combination of the selected tracer
		Sacrifice timepoint after injection
Imaging: capture and analysis	Captured images of the lymphatic circuit are not satisfactory	Dissection issue (lymph nodes are missing)
		Imaging issue

Solution
<ol style="list-style-type: none"> 1. Punctate with care, but fully, the dura mater with a 26 G needle before glass capillary insertion. 2. Reduce the deepness of glass capillary insertion (<1.5 mm from the dura mater). 3. Reduce the glass capillary diameter.
<ol style="list-style-type: none"> 1. Check if the glass micro capillary has been well inserted into the punctate the dura mater. 2. Add surgical glue between glass microcapillary and the surrounded tissue before injecting tracer.
Reduce the volume of injected tracer (<2 μ L).
<p>Increase the number and/or the time of incubation steps: permeabilization, whashing, primary antibody and clearing. See http://www.idisco.info (FAQ AND TROUBLESHOOTING).</p>
Use a more stringent decalcification treatment of sample with EDTA ²¹ or Morse solution for head tissues especially.
Use fresh H ₂ O ₂ solution, increase volume and/or incubation time.
Fill the tube completely to avoid the presence of air.
Increase volume and/or incubation time. See http://www.idisco.info (FAQ AND TROUBLESHOOTING).
Alexa 555, 594 and 647 fluorochromes are resistant to iDISCO ⁺ protocol ⁵⁻¹⁰ . However, this is not the case for FITC, GFP, RFP fluorochromes.
Prefer OVA-A ⁵⁵⁵ for short-term (15 min) drainage analysis in local vertebral lymphatics. For lymph nodes drainage analysis, OVA-A ⁵⁵⁵ and Lyve1 antibody can be used for longer term (>45 min) analysis.
Include carefully the vertebral/skull neighboring tissues in your dissected sample, according to the lymphatic circuit that you want to image.
<ol style="list-style-type: none"> 1. Modify the acquisition parameters of the LSM: laser intensity, light-sheet numerical aperture, thickness of light-sheet, exposition time. 2. Place the sample in the support to reduce the path travelled by light through the tissue until the objective. 3. Be sure that there are no bubbles inside the tissue sample during acquisition.

Name of Material/Equipment**Consumables**

Centrifuge tubes: 0.2ml
 Centrifuge tubes: 2ml
 Conical centrifuge tubes: 15ml
 Conical centrifuge tubes: 50ml
 Microtome blade 80mm
 Needles 26G (0.45x13 mm)
 Syringe 1ml

Microscopes and imaging softwares

AxioZoom.V16 fluorescence stereo zoom microscope, equipped with an ORCA-Flash 4.0 digital sCMOS camera (Hamamatsu Photonics) or an OptiMOS sCMOS camera
 Inspector Microscope controller software, Version v144-(acquisition software)
 Imaris File Converter x64 9.2.0(file conversion software) , Imaris stitcher software 9.2.0 (stitcher software), Imaris x64 9.2.0 (3D software)
 LED lasers (OBIS) LVBT Laser module 2nd generation
 Ultramicroscope II equipped with a sCMOS camera (Andor Neo) and a 4 × /0.3 objective lens (LVN

Reagents

Alexa Fluor 568 Donkey anti Rabbit
 Alexa Fluor 647 Donkey anti goat
 Alexa Fluor 647 Donkey anti Rabbit
 Anti-LYVE1 polyclonal antibody
 Anti-PROX1 goat polyclonal IgG antibody
 Buprenorphine Injection Ampoules (Buprecare solution, 0.3mg/ml)
 Dibenzyl Ether 100% (DBE)
 Dichloromethane 100% (DCM)
 Formic acid 99%
 Glycine
 Heparine sodium salt from porcine
 Hydrogen peroxide solution (H₂O₂ 30%)
 Isoflurane (Iso-Vet 100%)
 Methanol 100%
 Ovalbumin Alexa Fluor 555 Conjugate
 Phosphate Buffer Solution PBS (stock solution 10X)
 Sodium Pentobarbital (Euthasol 400mg/mL)
 Tri-sodium citrate

Surgical tools and equipments

Anaesthesia system
 Glass micropipette puller
 Heating pad
 Microcapillaries (Glass Capillaries)
 Microforceps, forceps, dissection scissors and Michel Suture Clips (7.5 × 1.75mm)
 Scalpel (sterile disposable scalpel 23)
 Stereotaxic apparatus
 Syringe Hamilton 10µl 701N
 Warm air System

Company	Catalog Number
---------	----------------

Eppendorf	30124359
Eppendorf	30120094
Falcon	352096
Falcon	352070
Microm Microtech France	F/MM35P
Terumo	AN*2613R1
Terumo	SS+01H1

Zeiss
Abberior instruments
OXFORD instruments

COHERENT
LaVision Biotec

Thermo Fisher	A10042
Jackson ImmunoResearch	705-605-147
Jackson ImmunoResearch	711-605-152
Angiobio	#11-034
R&D systems	#AF2727
Animalcare	Ampule 1ml
Sigma Aldrich	108014
Sigma Aldrich	270997
CARLO ERBA	405793
Sigma Aldrich	G.7126
Sigma Aldrich	H4784
Sigma Aldrich	H1009
Piramal	NDC 66794-013-10
Sigma Aldrich	322415
Invitrogen	11549176
Euromedex	ET330-A
Dechra	08718469445110
VWR	6132-04-3

Univentor	Univentor 410 Anaesthesia Unit
Narishige	PC-10
CMA Microdialysis AB	CMA 450 Temperature controller
Harvard Apparatus	GC120-15
Fine Science Tool	12040-01
Swann-Norton	0510
KOPF	Model 940
Hamilton	28618-U
Vet-Tech LTD	HE011

Dear Dr. Cao,

our manuscript, JoVE61099R1 "Three-dimensional imaging of the CNS-associated lymphatic vasculature and drainage using the iDISCO+ protocol and light sheet fluorescence microscopy," has been revised according to your following comments which have been addressed. Please track the changes to identify all of the manuscript edits. The revised submission is associated with separate document that addresses each of the editorial comments individually with the revised manuscript.

Thank you for your helpful review.

Best,

Jean-Leon Thomas

Editorial comments:

1. Please note that the editor has formatted the manuscript to match the journal's style. Please retain the same. The updated manuscript is attached and please use this version to incorporate the changes that are requested.

Thank you for having reformatted the manuscript

2. Please address specific comments marked in the attached manuscript.

We have addressed the following comments:

Line 135: the dilution of secondary antibodies is indicated '(same 1/2,000 dilution)'

Line 146: we now state: 'Anaesthetize the mouse in an induction box with 2–3% isoflurane gas'.

Line 173: we have added '(see step 1.2)' following 'the glass capillary tip'

Line 258: we confirm that 100% methanol was not used in step 6.3.1, as samples were in 83% methanol in the previous step 6.2.1. Dehydration starts in 80% methanol.

Lines 264-265: we confirm that 2 successive incubations of 1h each in PTx2 solution are required and have added 'renew for the second incubation'.

Line 277: we confirm that dilution of heparin is in 1x PBS.

Lines 278 and 281: we corrected 'until the next day' by 'overnight'

Line 291: we corrected 'Incubate' by 'wash ...to remove'

Lines 317-319: step 7.5, we have briefly explained how to perform the procedure of the mosaic reconstruction: 'The images are opened with the software and moved manually to reconstitute the whole mosaic picture, using the 10% overlap between images as a guideline.'

Lines 312: step 7.4, we deleted 'apply a gammaLSFM' in Line 312 and added 'Set a gamma correction of 1.47 to the raw data obtained from the LSFM (see <https://imaris.oxinst.com/tutorials>) in Line 323-325.

Line 375: we refer to Figure 3C after 'lymphatic vessels' at the end of the sentence.

Lines 476-478: we have rephrased the sentence in order to not mention the expression 'conventional approaches' which include all the classical methods of immunohistology and imaging which do not take advantage of virtual reality. The sentence now reads as 'LSFM imaging thus needs to be extended by virtual reality tools which enable interactive visualization and thus facilitate quantification of the lymphatic vasculature (see www.syglass.io).

Line 501-502: We confirm that we refer to the Supplementary Figure 5 of our original manuscript (ref 14)

3. Please use the attached template of Table of Materials and include Name of Material/Equipment, Company and Catalog Number for each commercial product in separate columns. Sort the materials alphabetically by material name. Do not number the Table of Materials in the article. Do not include any TM/[®]/[©] symbols here.

The Table of Materials has been reordered according to your recommendations and is no more numerated in the text, which now includes only Table 1 (Line 450) and Table 2 (Line 552).

4. I highlighted ~3 pages of the protocol for filming. Please review. Note that the highlighted content should contain essential steps of the protocol for the video, i.e., the steps that should be visualized to tell the most cohesive story of the Protocol. Please ensure that the highlighted steps form a cohesive narrative with a logical flow from one highlighted step to the next. Please note that I have made some minor changes (e.g., combining some shorter steps) to condense the highlighted content.

We thank you for your edits which have improved the cohesion of the narrative. We agree with the highlighted paragraphs to be visualized in the video as the key steps of the protocol. We have however added the step 2.1.3 'Anaesthetize the mouse in an induction box with 2–3% isoflurane gas', as the first sequence introducing the movie.

Jean-Leon THOMAS, PhD., is Associate Professor at the Department of Neurology, Yale University School of Medicine (New Haven, USA), and Director of Research at INSERM in the team “Alzheimer’s and Prion Diseases’ at the Institut du Cerveau et de la Moelle epiniere (ICM, Paris, France).

JL Thomas’s research focuses on the biology of glial cells, neural stem cells and on the crosstalk between these cells and the vascular network. He is currently using 3D-brain imaging to explore the role of meningeal and epidural lymphatics in nervous system diseases.

Recent publications: 1) Song E et al., *Nature*, in the press; 2) Jacob L et al., *Nature Commun.* 2019 doi: 10.1038/s41467-019-12568-w.; 3) Genet G et al., *Nature Commun.* 2019 doi: 10.1038/s41467-019-10359-x; 4) Antila S et al., *JEM* 2017 doi: 10.1084/jem.20170391; 5) Han J et al, *Cell Rep.* 2015 doi: 10.1016/j.celrep.2015.01.049

Complete list of publications:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/jean.thomas.1/bibliography/48463458/public/?sort=date&direction=ascending>.

Laurent Jacob, PhD., is postdoctorant fellow in the laboratory of JL Thomas at ICM (Paris). L. Jacob is expert in the biology of neurovascular interactions and combines *in vivo* approaches and advanced 3D-imaging techniques for their study.

Main publications: 1) Jacob L et al., *Nature Commun.* 2019 doi: 10.1038/s41467-019-12568-w;

2) Binaime F et al, *EMBO Mol Med.* 2019 doi: 10.15252/emmm.201910378; 3) Jacob L et al, *Oncotarget* 2016 doi: 10.18632/oncotarget.11072.

Nicolas Renier, PhD., is Director of Research at INSERM and head of the team “Structural plasticity’ at the Institut du Cerveau et de la Moelle epiniere (ICM, Paris, France). N. Renier’s research focuses on neurodevelopment and neurovascular interactions in health and diseases, and he has developped inovative 3D-imaging approaches for their exploration.

Main publications: 1) Renier N et al, *Elife* 2017 doi: 10.7554/eLife.23494; 2) Renier et al, *Cell* 2016 doi: 10.1016/j.cell.2016.05.007; 3) Renier N et al *Cell* 2014 doi: 10.1016/j.cell.2014.10.010; Renier et al, *Plosbiol* 2010 doi: 10.1371/journal.pbio.1000325.

Jose Brito, PhD, is Associate Professor at the Federal University of Rio de Janeiro (UFRJ, Brazil) and visiting fellow in the laboratory of JL Thomas at ICM (Paris). J. Brito is an expert in micro-neurosurgery and a specialist of neurodevelopment in vertebrates.

Main publications: 1) Jacob L et al., *Nature Commun.* 2019 doi: 10.1038/s41467-019-12568-w; 2) Brito J et al, *Development* 2008 doi: 10.1242/dev.019125; 3) Brito J et al, *Proc Natl Acad Sci U S A.* 2006.



1 Alewife Center #200
Cambridge, MA 02140
tel. 617.945.9051
www.jove.com

ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: **Three-dimensional imaging of the CNS-associated lymphatic vasculature using the iDISCO+ protocol and light sheet fluorescence microscopy**
Author(s): **Jacob L, Brito J, Renier N, Thomas JL**

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐

Standard Access

☒

Open Access

Item 2: Please select one of the following items:

☒

The Author is **NOT** a United States government employee.

☐

The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.